Predictive factors for serological response in HbeAg-positive chronic hepatitis B patients with adefovir dipivoxil treatment

( views:, downloads: )
Author:
GAO Hai-bing(Department of Hepatology,Fuzhou Municipal Hospital of Infectious Diseases,Fujian Medical University,Fuzhou 350025,China)
PAN Chen(Department of Hepatology,Fuzhou Municipal Hospital of Infectious Diseases,Fujian Medical University,Fuzhou 350025,China)
LIN Ming-hua(Department of Hepatology,Fuzhou Municipal Hospital of Infectious Diseases,Fujian Medical University,Fuzhou 350025,China)
ZHOU Rui(Department of Hepatology,Fuzhou Municipal Hospital of Infectious Diseases,Fujian Medical University,Fuzhou 350025,China)
ZHENG Lin(Department of Hepatology,Fuzhou Municipal Hospital of Infectious Diseases,Fujian Medical University,Fuzhou 350025,China)
LIN Tai-jie(Department of Hepatology,Fuzhou Municipal Hospital of Infectious Diseases,Fujian Medical University,Fuzhou 350025,China)
XU Li-jun(Department of Hepatology,Fuzhou Municipal Hospital of Infectious Diseases,Fujian Medical University,Fuzhou 350025,China)
YUAN Jin-jin(Department of Hepatology,Fuzhou Municipal Hospital of Infectious Diseases,Fujian Medical University,Fuzhou 350025,China)
FANG Jian-kai(Department of Hepatology,Fuzhou Municipal Hospital of Infectious Diseases,Fujian Medical University,Fuzhou 350025,China)
Journal Title:
CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
Issue:
Volume 02, Issue 06, 2009
DOI:
10.3760/cma.j.issn.1674-2397.2009.06.003
Key Word:
Chronic hepatitis B;Hepatitis B e antigens;Tumor necrosis factor-alpha;Adefovir dipivoxil

Abstract: Objective To investigate the predictive value of TNFα,ALT,HBV DNA loads and HBV serological markers in response to adefovir dipivoxil (ADV) treatment for patients with chronic hepatitis B(CHB).Methods Two hundred and three HBeAg.positive CHB patients were administered with ADV 10 mg/d for 48 weeks.HBV serological markers and TNFα at the baseline were determined by enzyme linked immunosorbent assay(EUSA),and HBV DNA loads were detected by PCR.Logistic regression was used to identify predictive factors for serological response at 48th week after the treatment.Results The rates of HBV DNA clearance,ALT normalization,HBeAg lOSS,HBeAg seroconversion and response at 24th week were 31.5%(64/203),59.1%(120/203),15.8%(32/203).8.9%(18/203)and 13.3%(27/203)respectively,while those at 48th week were 58.6%(119/203),78.3%(159/203),29.6%(60/203),16.7%(34/203)and 25.6%(52/203),respectively.Patients who achieved HBeAS loss at 48th week were found to have higher rates of HBV DNA clearance.HBeAg loss and seroconversion at 24th week and higher TNFα at baseline(P=0.017,0.ooI,0.029 and 0.040),while those who achieved HBeAg seroconversion at 48th week were found to have higher rate of HBeAg seroconversion at 24th week.and lower baseline HBV DNA loads(P=0.000 and 0.004).Conclusion For HBeAg.positive CHBpatients with ADV treatment,the rate of HBV DNA clearanee,HBeAg loss and seroeonversion at 24th week and TNFα at baseline may be used to predict the rate of HBeAg 1088 at 48th week:the rate of HBeAgseroconversion at 24th week and baseline HBV DNA loads may be used to predict the rate of HBeAgseroeonversion at 48th week.

  • [1]Tillmann HL.Antiviral therapy and resistance with hepatitis B virus infection.World J Gastroenterol,2007,13(1):125-140.
  • [2]Puro R,Schneider RJ.Tumor neciDflis factor activates a conserved innate antiviral response tO hepatitis B rims that destabilizes nueleocapsids and reduces nuclear viral DNA.J Virol,2007,81(14):7351-7362.
  • [3]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment fon chronic hepatitis B.Zhonghua Ganzangbing Zazhi,2005,13(12):881-891.(in Chinese)中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南.中华肝脏病杂志,2005,13(12) =881-891.
  • [4]Ou Q,Zhu SB,Yin KS.Efficacy and safety of adefovir for treating HBeAg positive chronic hepatitis B.Ganzang,2007,12(5):423-424.(in Chinese)欧强,诸思贇,殷科珊.阿德福韦酯治疗e搞原阳性慢性乙型肝炎患者疗效和安全性观察.肝脏,2007,12(5):423-24.
  • [5]Akarca U S.Chronic hepatitis B.A guideline to diagnosis,approach,management,and follow-up 2007.Turkish Associationfor the Study of Liver.Turk J Gastroenterol,2008,19 (4):207-230.
  • [6]Kasahara S,Ando K.Saito K,et al.Lack of tumor necrosis factor-alpha induces inpaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes.J Virol,2003,77(4):2469-2476.
  • [7]Pasquetto V.Wieland SF,Uprichard SL.et al.Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures.J Virol,2002,76(11):5646-5653.
  • [8]Rigopoulou EI,Suri D,Chokshi S,et al.Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B:antiviral and immunological activity.Hepalology,2005,42(5):1028-1036.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn